Role of bone-forming agents in the management of osteoporosis

被引：28
|
作者：
McClung, Michael R. [1 ,2 ]
机构：
[1] Oregon Osteoporosis Ctr, Portland, OR 97225 USA
[2] Australian Catholic Univ, Mary MacKillop Ctr Hlth Res, Melbourne, Vic, Australia
来源：
AGING CLINICAL AND EXPERIMENTAL RESEARCH | 2021年 / 33卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Osteoporosis; Osteoanabolic; Abaloparatide; Romosozumab; Teriparatide; Sequence;
D O I：
10.1007/s40520-020-01708-8
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
Recent evidence confirms the superiority of osteoanabolic therapy compared to anti-remodeling drugs for rapid improvement in bone density and fracture risk reduction, providing strong justification for the use of these anabolic agents as the initial therapy in high-risk patients, to be followed by anti-remodeling therapy. This review will highlight the results of recent studies and define the current status of osteoanabolic therapy for osteoporosis.
引用
收藏
页码：775 / 791
页数：17
相关论文
共 50 条
  • [1] Role of bone-forming agents in the management of osteoporosis
    Michael R. McClung
    Aging Clinical and Experimental Research, 2021, 33 : 775 - 791
  • [2] Bone-forming agents in the management of osteoporosis
    Neuprez, Audrey
    Reginster, Jean-Yves
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (05) : 869 - 883
  • [3] Treatment of Osteoporosis: Role of Bone-Forming Agents
    J.-Y. Reginster
    V. Halkin
    Y. Henrotin
    C. Gosset
    Osteoporosis International, 1999, 9 (Suppl 2) : S91 - S96
  • [4] Bone forming agents for the management of osteoporosis
    Reginster, J. Y.
    Neuprez, A.
    Beaudart, Ch.
    Buckinx, F.
    Slomian, J.
    Disteche, S.
    Bruyere, O.
    PANMINERVA MEDICA, 2014, 56 (02) : 97 - 114
  • [5] The role of osteoanabolic agents in the management of patients with osteoporosis
    McClung, Michael R.
    Rothman, Micol S.
    Lewiecki, E. Michael
    Hanley, David A.
    Harris, Steven T.
    Miller, Paul D.
    Kendler, David L.
    POSTGRADUATE MEDICINE, 2022, 134 (06) : 541 - 551
  • [6] The Role of Novel Bone Forming Agents in the Treatment of Osteoporosis
    Patel, Hansita B.
    Lyerly, Lynsie J.
    Horlen, Cheryl K.
    JOURNAL OF PHARMACY PRACTICE, 2021, 34 (06) : 952 - 961
  • [7] New bone-forming treatments for osteoporosis
    Papapoulos, Socrates E.
    NATURE REVIEWS ENDOCRINOLOGY, 2015, 11 (02) : 69 - 70
  • [8] Recommendations for the optimal use of bone forming agents in osteoporosis
    Veronese, Nicola
    Briot, Karine
    Guanabens, Nuria
    Albergaria, Ben Hur
    Alokail, Majed
    Al-Daghri, Nasser
    Bemden, Angie Botto-van
    Bruyere, Olivier
    Burlet, Nansa
    Cooper, Cyrus
    Curtis, Elizabeth M.
    Ebeling, Peter R.
    Halbout, Philippe
    Hesse, Eric
    Hiligsmann, Mickael
    Camargos, Bruno Muzzi
    Harvey, Nicholas C.
    Perez, Adolfo Diez
    Radermecker, Regis Pierre
    Reginster, Jean-Yves
    Rizzoli, Rene
    Siggelkow, Heide
    Cortet, Bernard
    Brandi, Maria Luisa
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 (01)
  • [9] Bone-forming agents in non-responders to bisphosphonates
    Compston, Juliet
    LANCET, 2017, 390 (10102) : 1565 - 1566
  • [10] A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis
    Soreskog, E.
    Borgstrom, F.
    Lindberg, I.
    Strom, O.
    Willems, D.
    Libanati, C.
    Kanis, J. A.
    Stollenwerk, B.
    Charokopou, M.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (07) : 1301 - 1311
12345